Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023
The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...
Aurinia
LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™
May 10, 2021
The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing...
Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback
April 20, 2021
At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an...
Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020
One of the largest meetings for rheumatologists went virtual this year to enable scientists from around...
LRA Shares Excitement For What’s Ahead in Lupus Nephritis
January 16, 2020
Up to half of people with lupus will have lupus nephritis – damage to the kidneys that...
LRA Celebrates Major Research Breakthroughs in 2019
January 7, 2020
2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science...
Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid
November 8, 2019
Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact...
Good News from Aurinia Pharmaceuticals for Lupus Nephritis
September 25, 2018
Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of...
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global...